ABSTRACT
Objetivo:Avaliar o gasto energético e as medidas antropométricas de mulheres durante o primeiro ano de uso do método contraceptivo de acetato de medroxiprogesterona de depósito.Métodos:Estudo prospectivo com grupo de comparação. Foram incluídas mulheres saudáveis, não obesas, nunca usuárias de acetato de medroxiprogesterona de depósito e sem antecedentes que pudessem contribuir para a variação do peso corporal; foram distribuídas em dois grupos, 28 usuárias de acetato de medroxiprogesterona e 24 usuárias de dispositivo intrauterino de cobre, pareadas por idade (±1 ano) e índice de massa corporal (kg/m2). As variáveis estudadas foram sociodemográficas (idade, etnia, tabagismo, etilismo, atividade física, classe econômica e escolaridade), peso (kg), índice de massa corporal, gasto energético basal e total, medidas de circunferência de cintura e quadril (cm) e relação cintura-quadril.Resultados:A idade das mulheres variou de 20-39 anos. As médias de idade/índice de massa corporal foram 29,6 (DP=±5,2) anos/23,9 (±3,6 kg/m2), no grupo de acetato de medroxiprogesterona de depósito, e de 28,6 (DP=±5,2) anos/ 24,5 (±2,7 kg/m2), no grupo de dispositivo intrauterino de cobre. Após análise de variância para medidas repetidas, as usuárias de acetato de medroxiprogesterona de depósito apresentaram ganho de 2,2 kg no peso corporal e de -0,2 kg no grupo do dispositivo intrauterino de cobre, sem diferença estatisticamente significativa entre eles. Não houve discrepância nas demais variáveis estudadas.Conclusão:Mulheres saudáveis e jovens não apresentaram mudança no peso, nas medidas e nos gastos energéticos durante o primeiro ano de uso do contraceptivo acetato de medroxiprogesterona. A orientação em relação aos hábitos saudáveis de vida e o monitoramento de medidas são importantes para o controle do peso corporal em usuárias de métodos contraceptivos.
Objective:The objective of this study was to assess energy expenditure and the anthropometric profile of women during the first year of use of depot medroxyprogesterone acetate contraception.Methods:This prospective study included healthy non-obese women who had never used depot-medroxyprogesterone acetate and did not have a history of weight fluctuations. The women were divided into two groups composed of 28 depot medroxyprogesterone acetate users and 24 copper intrauterine device (TCu380A) users. They were paired for age (+1 year) and body mass index (+1 kg/m2). The following variables were used: sociodemographic characteristics (age, ethnicity, smoking status, alcohol consumption, physical activity, economic class, and education level), weight (kg), body max index, resting and total energy expenditure, waist and hip circumferences (cm), and waist-to-hip ratio.Results:The age of the women studied ranged from 20-39 years. The mean values of age/body mass index ratio were 29.6 (SD=+5.2) years/23.9 (+3.6 kg/m2) in the depot medroxyprogesterone acetate group and 28.6 (SD=+5.2) years/24.5 (+2.7 kg/m2) in the intrauterine device group. After conducting repeated measures analysis of variance, the users of depot medroxyprogesterone acetate showed weight gain of 2.2 kg, and those in the intrauterine device group showed weight loss of 0.2 kg without statistically significant difference between the groups. There were no significant differences between the other variables.Conclusion:There were no changes in weight, anthropometric measurements, and energy expenditure in the young and healthy women during the first year of use of depot medroxyprogesterone acetate contraception. Guidelines and recommendations for a healthy lifestyle to avoid changes in the anthropometric measurements are important for weight control in users of contraceptive methods.
Subject(s)
Humans , Female , Adult , Body Weight/drug effects , Medroxyprogesterone Acetate/adverse effects , Energy Metabolism/drug effectsABSTRACT
OBJECTIVES: To evaluate weight gain and body composition (BC) in new users of depot-medroxyprogesterone acetate (DMPA) as a contraceptive. METHODS: This cohort study followed up 20 DMPA users and 20 copper intrauterine device (TCu380A IUD) users, paired for age (± 1 year) and body mass index (BMI ± 1 kg/m(2)), during 12-months. Healthy, non-obese women aged 18 to 40 years, unaffected by conditions that could influence their body weight, were enrolled. Socio-demographic variables, habits, weight, BMI, BC using dual-energy X-ray absorptiometry, circumferences, skinfold thickness, body fat percentage and waist-to-hip ratio were evaluated. All participants were encouraged to adopt healthy habits. RESULTS: At baseline, median age was 29 and 30.5 years, and mean BMI was 24.8 and 24.5 kg/m(2) in the DMPA and IUD groups, respectively. At 12 months, an increase was observed in waist and hip circumference in the DMPA users and 8/20 of them had a weight gain ≥ 5% (mean 4.6 kg) with accumulation of fat centrally. CONCLUSIONS: There were no differences in weight gain or in BC measurements between the groups; nevertheless 40% of women in the DMPA group had larger weight gain and accumulation of fat centrally. The duration of follow-up may have been insufficient to detect differences between the groups.
Subject(s)
Body Composition/drug effects , Contraceptive Agents, Female/adverse effects , Medroxyprogesterone Acetate/adverse effects , Weight Gain/drug effects , Adolescent , Adult , Body Mass Index , Contraceptive Agents, Female/administration & dosage , Female , Follow-Up Studies , Humans , Injections , Intrauterine Devices/adverse effects , Medroxyprogesterone Acetate/administration & dosage , Young AdultABSTRACT
OBJECTIVE: To evaluate the effect of functional constipation on women with and without chronic pelvic pain (CPP). STUDY DESIGN: One hundred women ages 18-50 were separated into three groups: (A) women without CPP, (B) women with CPP but without functional constipation, and (C) women with CPP with functional constipation according to Rome III criteria. All participants were followed over 3 months, completing a questionnaire on pain and constipation daily. CPP was evaluated using a visual analog scale (VAS). RESULTS: In Group A, 16 of 31 women complained of lumpy or hard stools; 13 had symptoms of functional constipation. In Group B, 4 of 19 women had lumpy or hard stools. In Group C, 46 of 50 reported straining or incomplete bowel movements and 49 reported lumpy or hard stools. Regarding CPP, no significant differences were found in VAS pain score between Groups B and C; no changes were found in VAS pain score throughout the 12-week evaluation period. The most common diagnoses associated with CPP were idiopathic pain, endometriosis, and pelvic adhesions. CONCLUSION: Functional constipation was significantly more prevalent in women with CPP than women without CPP; however, it does not appear to have a role in worsening the pain.
